CN113713084A - Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people - Google Patents

Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people Download PDF

Info

Publication number
CN113713084A
CN113713084A CN202111202437.XA CN202111202437A CN113713084A CN 113713084 A CN113713084 A CN 113713084A CN 202111202437 A CN202111202437 A CN 202111202437A CN 113713084 A CN113713084 A CN 113713084A
Authority
CN
China
Prior art keywords
parts
calcium
type
collagen peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111202437.XA
Other languages
Chinese (zh)
Inventor
易跃能
邓义德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUNAN YINENG BIOLOGICAL PHARMACEUTICAL CO Ltd
Original Assignee
HUNAN YINENG BIOLOGICAL PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUNAN YINENG BIOLOGICAL PHARMACEUTICAL CO Ltd filed Critical HUNAN YINENG BIOLOGICAL PHARMACEUTICAL CO Ltd
Priority to CN202111202437.XA priority Critical patent/CN113713084A/en
Publication of CN113713084A publication Critical patent/CN113713084A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • A23L17/60—Edible seaweed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a composition for preventing osteoporosis and promoting bone health, which comprises the following components in parts by weight: 35-68 parts of type II collagen peptide; 0.6-15 parts of seaweed powder; 0.65-5 parts of a calcium source; 0.16-2.8 parts of casein phosphopeptide; 8.2-50 parts of auxiliary materials. The composition has very high absorptivity and strong pertinence, promotes the absorption and utilization of middle-aged and elderly people with weak digestion and absorption functions, and accelerates the repair of degenerated bones.

Description

Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people
The application is a divisional application of a composition for preventing osteoporosis and promoting bone health, and the application date of the original application is 2018.02.08, the application number is 201810125823.5 and the invention provides the composition for preventing osteoporosis and promoting bone health.
Technical Field
The invention relates to a composition for preventing osteoporosis and promoting bone health, and belongs to the field of food/health-care food.
Background
Osteoporosis is a worldwide health problem that is becoming more and more appreciated by people. At present, about 2 hundred million people all over the world suffer from osteoporosis, and the incidence rate thereof is leaped to the seventh of common diseases and frequently encountered diseases. Recent research shows that osteoporosis which is considered as a specific disease of the elderly in China all the time has 6000 to 8000 ten thousand, and along with the aging of population, the osteoporosis seriously affects the life and health of residents due to high morbidity, high disability rate and high mortality, and gradually becomes a serious public health problem.
Modern researches show that old people have insufficient intake of calcium, vitamins and trace elements due to tooth loss, insufficient gastric acid secretion or gastric acid deficiency, reduced digestive function, poor bone-taking capability, reduced nutrient intake and more nutrient deficiency. The habit diet in China belongs to a low-calcium diet, the calcium source mainly depends on grains and vegetables, the old people have more deficiency, the vegetables, fruits and lean meat are not easy to chew, the intake is reduced, and the negative calcium balance is presented. In recent years, a large number of health-care food or pharmaceutical preparations for preventing, improving or assisting the treatment of osteoporosis appear in the market, but the health-care food or pharmaceutical preparations do not have the characteristics of the old, have low general absorption rate or large side effect, and the calcium which is excessively ingested can be combined with oxalic acid-containing substances such as ingested vegetables to form calcium acetate stones because the calcium cannot be sufficiently absorbed, so that the calcium acetate stones are harmful to the human body. The enhanced high-density products in the market, one type, which are used for directly supplementing calcium components to enhance the absorption of human bodies to calcium, have generally low absorption rate, are quite part of the products which adopt calcium carbonate and the like which need to consume gastric acid and have poor water solubility, are not beneficial to absorption, and can cause the gastric acid of the old to be more deficient; one is calcium supplement and absorption enhancer, the calcium absorption rate is high, but because a proper calcium source and calcium absorption enhancer such as calcium carbonate with poor water solubility is not selected according to the characteristics of the old, for example, vitamin D is used as the calcium absorption enhancer, the metabolism time of the vitamin D in the human body is long, the metabolism function of many old people is relatively poor, and the vitamin D is easy to accumulate in the body, so that poisoning is caused.
Therefore, the development of a health food which has strong pertinence, high absorption rate and no side effect, is suitable for the old to take, can relieve the pain of patients and the family burden, and can avoid generating complications is an ideal way for preventing osteoporosis and promoting bone health.
Disclosure of Invention
The invention solves the technical problem of overcoming the defects of the existing products for increasing the bone mineral density, and prepares a safe, nutritional, efficient and stable composition for promoting the bone health by scientifically compounding the II-type collagen peptide, the natural organic marine plant calcium source-red seaweed powder and other raw materials with the function of increasing the bone mineral density.
The technical scheme of the invention is to provide a composition for preventing osteoporosis and promoting bone health, which comprises the following components in parts by weight:
Figure BDA0003305504230000021
preferably, the composition comprises the following components in parts by weight:
Figure BDA0003305504230000022
preferably, in the type II collagen peptide, the oligopeptide with the relative molecular weight of less than 1000 accounts for more than 80 percent of the total mass of the type II collagen peptide.
Preferably, the calcium source is one or more of bone meal, calcium aspartate, calcium lactate, L-calcium lactate, calcium citrate and calcium carbonate. More preferably, the calcium carbonate is a biological calcium carbonate.
Preferably, the type II collagen peptide is a product of enzymatic hydrolysis of type II collagen. Hydrolyzing type II collagen with type II collagen hydrolase to obtain type II collagen peptide, i.e. type II collagen polypeptide.
Preferably, the preparation method of the type II collagen peptide comprises the following steps: hydrolyzing the type II collagen by enzyme, inactivating the enzyme, centrifuging, and spray drying to obtain type II collagen peptide powder.
Preferably, the auxiliary materials are one or more of filling agents, sweeteners, edible essences and lubricants.
Preferably, the lubricant is selected from one or more of magnesium stearate, silicon dioxide and talc.
Preferably, the edible essence is selected from one or more of orange essence, lemon essence, strawberry essence, blueberry essence, apple essence, pineapple essence and milk essence.
Preferably, the sweetener is selected from one or more of stevioside, mogroside, sucralose and aspartame.
Preferably, the auxiliary material is uniformly mixed with the seaweed meal, the calcium source and the casein phosphopeptide, then the II type collagen peptide is added, and the composition for preventing osteoporosis and promoting bone health is obtained after uniform mixing.
The composition is applied to preventing osteoporosis and promoting bone health, and has a very good effect.
The seaweed powder is preferably red seaweed powder, is a natural organic marine plant calcium source, and is prepared from red seaweed growing in coastal seabed by extracting and refining, and is rich in other trace minerals such as magnesium, zinc, iron, phosphorus, boron, etc.
The composition for preventing osteoporosis and promoting bone health can be prepared into solid preparations. The solid preparation is preferably powder, granules, capsules and tablets.
The preparation method of the composition for preventing osteoporosis and promoting bone health comprises the following steps:
1) the processing technology of the collagen II peptide raw material comprises the following steps: II type collagen protein, enzyme hydrolysis, inactivation, centrifugation, spray drying and II type collagen peptide powder;
2) weighing the raw materials according to the formula of the product;
3) mixing: fully and uniformly mixing the sweetening agent, the essence and the filler, then adding the red seaweed powder, the calcium source and the casein phosphopeptide, uniformly mixing, and finally adding the type II collagen peptide and other residual auxiliary materials, and uniformly mixing;
4) subpackaging: and (5) bagging according to the packaging specification.
The key innovation point of the product is that the product has very high absorptivity and strong pertinence.
The invention has the beneficial effects that:
1. the II type collagen peptide has short peptide chain and small molecular weight, is easy to absorb, promotes the absorption and utilization of middle-aged and elderly people with weak digestion and absorption functions, and accelerates the repair of degenerated bones;
2. the red seaweed powder-natural organic marine plant calcium source has high safety and high absorption rate, is rich in magnesium, phosphorus, boron and other trace elements, synergistically promotes calcium absorption, and supplements other trace elements required by a human body while supplementing calcium;
3. the casein phosphopeptide (CPP) with a specific ratio is added to promote the absorption of calcium by a human body, has good water solubility and good thermal stability, is easy to be absorbed by the human body, and can enhance the combination and absorption of calcium by middle-aged and elderly people;
4. the II type collagen peptide is matched with a calcium source to promote bone repair, and calcium ions are attached to a repaired bone scaffold, so that the effects of reasonable utilization and bone density enhancement are achieved.
Detailed Description
The present invention is illustrated by the following examples, which should be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Other insubstantial modifications and adaptations of the present invention can be made without departing from the scope of the present invention.
Treating a collagen II peptide raw material:
step 1: dissolving type II collagen with 2 times of purified water, adding collagen hydrolase at 50 deg.C, and hydrolyzing at constant temperature for 4 hr;
step 2: heating to 95 ℃ and keeping for 10 minutes for enzyme deactivation treatment;
and step 3: 5000r/min, and performing centrifugal treatment;
and 4, step 4: spray drying to obtain II type collagen peptide powder
By detecting the II type collagen peptide powder obtained by the process, the content of oligopeptide is 88.2 percent, wherein the proportion of protein hydrolysate with the relative molecular weight of less than 1000u is 85.1 percent.
The seaweed meal adopted by the invention is purchased in the market
Figure BDA0003305504230000041
Seaweed meal, such as Shanghai Chengni-food materials Co., Ltd.
Example 1
The composition for preventing osteoporosis and promoting bone health provided by the embodiment 1 of the invention is prepared from the following components in parts by weight:
Figure BDA0003305504230000042
1) weighing the raw materials according to a formula;
2) mixing: fully and uniformly mixing stevioside, sweet orange essence and maltodextrin, then adding II-type collagen peptide, seaweed powder, calcium aspartate, casein phosphopeptide and sorbitol, uniformly mixing, and finally adding magnesium stearate, and uniformly mixing to obtain a total mixed material;
3) tabletting: tabletting the total mixed material to obtain plain tablets;
4) coating: preparing hydroxypropyl methylcellulose and polyethylene glycol 1000 into 10% (w/v) film coating solution, and coating plain tablets with the coating solution in a coating pan to obtain the final product.
Example 2
The composition for preventing osteoporosis and promoting bone health, which is provided by the embodiment 2 of the invention, is prepared from the following components in parts by weight:
Figure BDA0003305504230000051
1) weighing the raw materials according to a formula;
2) mixing: fully and uniformly mixing casein phosphopeptide, biological calcium carbonate and starch, adding II-type collagen peptide, seaweed powder and fructose (60 meshes), and uniformly mixing;
3) and (3) granulating: 75% of ethanol is used as a wetting agent, the dosage is 10%, and the granules are sieved by a 18-mesh sieve and granulated;
4) and (3) drying: the drying temperature is 60 ℃, and the moisture of the granules is controlled to be 3-4.5 percent;
5) straightening: sieving the dried granules with a 16-mesh sieve for finishing;
6) total mixing: uniformly mixing the whole particles with silicon dioxide;
7) filling a capsule: and (5) filling according to specifications.
Example 3
The composition for preventing osteoporosis and promoting bone health provided by embodiment 3 of the invention is prepared from the following components in parts by weight:
Figure BDA0003305504230000052
1) weighing the raw materials according to a formula;
2) mixing: fully and uniformly mixing sucralose, seaweed meal, calcium lactate and starch, adding II-type collagen peptide, casein phosphopeptide, skimmed milk powder and inulin, and uniformly mixing;
3) and (3) granulating: 60% of ethanol is used as a wetting agent, the dosage is 8%, and the granules are sieved by a 18-mesh sieve and granulated;
4) and (3) drying: the drying temperature is 60 ℃, and the moisture of the granules is controlled to be 3-4.5 percent;
5) straightening: sieving the dried granules with a 16-mesh sieve for finishing;
6) total mixing: gradually increasing and mixing the whole part of particles with the pineapple essence in equal amount, and then adding the rest particles and the talcum powder to be uniformly mixed;
7) subpackaging: subpackaging according to the packaging specification.
Example 4
The composition for preventing osteoporosis and promoting bone health provided by embodiment 4 of the invention is prepared from the following components in parts by weight:
Figure BDA0003305504230000061
1) weighing the raw materials according to a formula;
2) mixing: mixing aspartame, blueberry essence and dextrin, adding seaweed meal, bone meal and casein phosphopeptide, mixing, and adding type II collagen peptide and silicon dioxide;
3) subpackaging: subpackaging according to the packaging specification.
Application example I, the following tests prove that the bone mineral powder has the function of increasing bone mineral density:
animal testing
1. Purpose of experiment
Research shows that the invention has the effects of preventing osteoporosis and promoting bone health
2. Experimental drugs
Comparative 1 group (collagen peptide type ii 68%, adjuvant 32%), comparative 2 group (seaweed meal 15%, bone meal 2.5%, casein phosphopeptide 2.7%, adjuvant 79.8%), comparative 3 group (collagen peptide type ii 30%, seaweed meal 0.5%, biological calcium carbonate 1.55%, casein phosphopeptide 0.25%, adjuvant 67.7%), concrete example 4.
3. Laboratory animal
The SPF SD rat is 50 female rats, 10 rats in each group, the body mass is 60-75 g, and the production license number of the experimental animal is SCXK (Jing) 2014-0013 provided by the resource center of the experimental animal of the Chinese food and drug testing institute.
4. Experimental methods and results
4.1 preparing the feed: (1) the formula of the low-calcium basic feed refers to the technical specification for health food inspection and evaluation, 2003 edition, page 111. (2) Dosage groups are prepared by using low-calcium basic feed, and the dosage groups are mixed by expanding 10 times according to 8 g/day/design.
4.2 rats were randomly divided into 5 groups, low calcium control, control 1, control 2, control 3, and example 4. Test samples were administered orally for 3 months and the body mass and feed intake of each animal were recorded.
4.3 body Mass measurement after 12h of fasting, body mass was measured. 1 time per week.
4.4 femoral gravimetric determination animals were sacrificed after feeding for 3 months, the right femurs were dissected out, baked in an oven at 105 ℃ to constant weight, and the dry bone weight was measured.
4.5 measuring the bone calcium content and the feed calcium content according to an atomic absorption spectrophotometry.
4.6 femoral bone Density determination bone density was measured at the mid-point of the femur and distal end of the femur using a bone densitometer (DISCOVEY WI AAL 286).
5. Statistical analysis: analysis of variance of each test group and the low calcium control group was performed using SPSS software.
TABLE 1 Effect of powder for preventing osteoporosis and promoting bone health on rat bone health
Figure BDA0003305504230000071
Note: p < 0.05 for comparison with low calcium control group
And (4) conclusion: as can be seen from Table 1, the difference between the bone calcium content item and the control group with low calcium has no statistical significance, the difference between the test group and the control group with low calcium has statistical significance for other items, and the indexes of the group in example 4 have better effect than those of the groups in comparison 1, 2 and 3.
Application example two, the edible effect of the invention, increasing the bone mineral density of middle-aged and elderly people
1. General data: the number of observation examples was 16. 6 men and 10 women. The age is 50-75 years old, and the bone density T is less than or equal to-2.5.
2. Testing an instrument: ultrasonic bone mineral density analyzer. Model X-36R dual energy X-ray bone densitometer, NORLAND, usa.
3. Detection of the site: the distal third of the radius.
4. Observation indexes are as follows: bone density T value.
5. The observation method comprises the following steps: 0 month, 1 day before eating; 3 months, eating for 3 months next day; 6 months, eating for 6 months next day; each test was performed 1 time.
6. The eating method comprises the following steps: 8 g/time and 1 time/day.
7. Observation unit: the fourth hospital in Changsha.
8. And (4) observing results: after eating the product of the invention for 3 months, the bone density value of the osteoporosis patients is close to normal, and the bone density value of the osteoporosis patients is completely normal after 6 months, and the results are detailed in table 2.
9. And (4) conclusion: the invention has the function of obviously increasing the bone mineral density
TABLE 2 Effect of the product on osteoporosis in middle aged and elderly people's bone mineral density
Figure BDA0003305504230000081
The invention has edible effect and has effect on arthralgia of middle-aged and elderly people with osteoporosis
1. The study subjects randomly selected 113 cases of chief complaints of arthralgia and osteoporosis patients of middle-aged and old people of 50-70 years old in Changsha city as study subjects. Before the experiment, the health condition of the patients is evaluated, and 90 patients with normal blood, normal urine, normal liver and kidney functions and normal blood uric acid enter the experiment. 34 male and 56 female. The random number table method is divided into A, B, C3 groups, and each group contains 30 cases.
2. The pain evaluation method adopts a Visual Analogue Scale (VAS) method to evaluate the pain degree of the selected patients, the pain degree is expressed by 0-10 points, and the patients are required to score according to the pain conditions of the patients. Namely, two ends of a moving ruler with the length of about 10cm are respectively a 0-point and a 10-point, 0 represents no pain, 10 represents the most severe pain which is difficult to bear, the graduated side faces back to a patient during clinical use, the patient marks a corresponding position on the ruler which can represent the pain of the patient, and a recorder scores according to the marked position of the patient. The clinical evaluation is that 0-2 is regarded as "excellent", 3-5 is regarded as "good", 6-8 is regarded as "good", and more than 8 is regarded as "poor". Group A in 3 groups distributed randomly is blank control group; group B is group B supplemented with glucosamine chondroitin capsule (0.5 g/capsule, containing glucosamine hydrochloride 230mg, calcium carbonate 180mg, chondroitin sulfate 80mg, other adjuvants 10mg) of a certain manufacturer; group C is group 4 of the present invention, and was administered at 8 g/d. The VAS scores of each group were observed at different time points.
3. Statistical analysis multiple comparisons were performed using analysis of variance, and multiple comparisons between pairs were performed using the Bonferroni method t test. Statistical software SAS8.02 is adopted for data operation. P < 0.05 is statistically significant.
Table 3.3 comparison of VAS scores for different time points in the groups of patients (n-30,
Figure BDA0003305504230000082
)
group of 10d 20d 30d 60d
Group A 8.09±1.57 8.06±1.47 7.65+1.99 7.99+1.76
Group B 7.88±1.62 5.96±1.33 4.67±1.51▲ 4.15±1.29▲
Group C 6.23±1.28 4.61±0.76▲ 3.82±0.75▲ 2.94±1.05▲
Note: compared with group A, P is less than 0.05
The results show that the effect of the composition on relieving the osteoarticular pain caused by osteoporosis is better than that of the glucosamine chondroitin capsule. At 20d, VAS scores of the group 4 according to the invention were statistically different from those of the group A (P < 0.05), and joint pain was significantly improved on both day 30 and day 60 (P < 0.05). The glucosamine chondroitin capsule group has obvious improvement (P is less than 0.05) on 30 days and 60 days.

Claims (10)

1. The application of a composition in preparing a medicine for treating bone joint pain is characterized in that the composition comprises the following components in parts by weight:
35-68 parts of type II collagen peptide;
0.6-15 parts of seaweed powder;
0.65-5 parts of a calcium source;
0.16-2.8 parts of casein phosphopeptide;
8.2-50 parts of auxiliary materials.
2. Use of a composition according to claim 1 for the preparation of a medicament for the treatment of osteoarticular pain, wherein the osteoarticular pain is caused by osteoporosis.
3. Use of a composition according to claim 1 for the preparation of a medicament for the treatment of osteoarticular pain, wherein the osteoarticular pain is osteoarticular pain in the middle and old aged.
4. The use according to claim 1, wherein the composition consists of, in parts by weight:
in the II type collagen peptide, the oligopeptide with the relative molecular weight less than 1000 accounts for more than 80 percent of the total mass of the II type collagen peptide.
5. The use according to claim 1, wherein the type ii collagen peptide is an enzymatic hydrolysis product of type ii collagen.
6. The use of claim 1, wherein the type ii collagen peptide is prepared by: hydrolyzing the type II collagen by enzyme, inactivating the enzyme, centrifuging, and spray drying to obtain type II collagen peptide powder.
7. The use of claim 1, wherein the adjuvant is one or more of a bulking agent, a sweetener, a flavoring and a lubricant.
8. The use of claim 1, wherein the calcium source is one or more of bone meal, calcium aspartate, calcium lactate, L-calcium lactate, calcium citrate, and calcium carbonate.
9. The use according to claim 1, wherein the calcium carbonate is a biological calcium carbonate.
10. The application of a composition in preparing a medicine for treating osteoporosis of middle-aged and elderly people is characterized in that the composition comprises the following components in parts by weight:
35-68 parts of type II collagen peptide;
0.6-15 parts of seaweed powder;
0.65-5 parts of a calcium source;
0.16-2.8 parts of casein phosphopeptide;
8.2-50 parts of auxiliary materials.
CN202111202437.XA 2018-02-08 2018-02-08 Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people Pending CN113713084A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111202437.XA CN113713084A (en) 2018-02-08 2018-02-08 Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111202437.XA CN113713084A (en) 2018-02-08 2018-02-08 Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people
CN201810125823.5A CN108378374A (en) 2018-02-08 2018-02-08 A kind of pre- preventing bone rarefaction, the composition for promoting bone health

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201810125823.5A Division CN108378374A (en) 2018-02-08 2018-02-08 A kind of pre- preventing bone rarefaction, the composition for promoting bone health

Publications (1)

Publication Number Publication Date
CN113713084A true CN113713084A (en) 2021-11-30

Family

ID=63074621

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111202437.XA Pending CN113713084A (en) 2018-02-08 2018-02-08 Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people
CN201810125823.5A Pending CN108378374A (en) 2018-02-08 2018-02-08 A kind of pre- preventing bone rarefaction, the composition for promoting bone health

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810125823.5A Pending CN108378374A (en) 2018-02-08 2018-02-08 A kind of pre- preventing bone rarefaction, the composition for promoting bone health

Country Status (1)

Country Link
CN (2) CN113713084A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109288064A (en) * 2018-10-10 2019-02-01 宝健（北京）生物技术有限公司 A kind of vitamin K composition, including its calcium balance preparation and application
CN112816697A (en) * 2019-11-18 2021-05-18 中国科学院分子细胞科学卓越创新中心 Reagent for inhibiting osteoclast activity and treating osteoporosis and application thereof
CN110786520A (en) * 2019-12-03 2020-02-14 武汉跃莱健康产业有限公司 Collagen calcium peptide powder and preparation method thereof
CN111467481A (en) * 2020-05-08 2020-07-31 江苏新中基生物科技有限公司 Composition for improving and/or preventing osteoarthritis and application thereof
CN113729230A (en) * 2020-05-29 2021-12-03 安琪纽特股份有限公司 Composition for preventing osteoporosis or enhancing bone mineral density and preparation and application thereof
CN111557451A (en) * 2020-06-02 2020-08-21 厦门肽王基因科技有限公司 Novel composite short peptide assembly
CN112586746A (en) * 2021-01-08 2021-04-02 金建文 Nutritional composition for simultaneously regulating bone and muscle health
CN116035152A (en) * 2023-02-13 2023-05-02 安徽中志科技有限公司 Selenium-enriched seaweed powder solid beverage

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101695382A (en) * 2009-10-30 2010-04-21 洛阳新春都生物制药有限公司 Calcium supplementing preparation with functions of improving bones and joints
CN103520711A (en) * 2013-10-24 2014-01-22 北京一品堂医药科技有限公司 Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition
CN103583943A (en) * 2013-10-10 2014-02-19 青岛贝尔特生物科技有限公司 Formula of healthcare product for increasing bone mineral density
CN104162150A (en) * 2014-07-23 2014-11-26 北京中泰天和科技有限公司 Composition having bone mineral density increasing function and preparation method thereof
CN105363023A (en) * 2015-11-11 2016-03-02 深圳太太药业有限公司 Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781672A (en) * 2010-04-13 2010-07-21 北京华达杰瑞生物技术有限公司 Process for preparing hydrolyzed II-type collagen
CN102077942B (en) * 2010-09-20 2013-04-24 王强 Marine special dietary food special for patient with bone disease
KR20130011515A (en) * 2011-07-22 2013-01-30 박영엽 Health care food comprised of spirulina and product method of it

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101695382A (en) * 2009-10-30 2010-04-21 洛阳新春都生物制药有限公司 Calcium supplementing preparation with functions of improving bones and joints
CN103583943A (en) * 2013-10-10 2014-02-19 青岛贝尔特生物科技有限公司 Formula of healthcare product for increasing bone mineral density
CN103520711A (en) * 2013-10-24 2014-01-22 北京一品堂医药科技有限公司 Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition
CN104162150A (en) * 2014-07-23 2014-11-26 北京中泰天和科技有限公司 Composition having bone mineral density increasing function and preparation method thereof
CN105363023A (en) * 2015-11-11 2016-03-02 深圳太太药业有限公司 Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.BAKRIASSOUMANI: "新型天然海藻钙源", 《中国食品工业》 *

Also Published As

Publication number Publication date
CN108378374A (en) 2018-08-10

Similar Documents

Publication Publication Date Title
CN113713084A (en) Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people
TW200942228A (en) Oral or enteral composition useful for recovery of physical functions
WO2011077800A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
JP7281031B2 (en) Composition for ameliorating persistent attention deficit associated with aging
JP6218732B2 (en) Composition for preventing or treating osteoarthritis
Deo et al. Absorption of Co58 Labeled Cyanocobalamin in Protein Deficiency: An Experimental Study in the Rhesus Monkey
CN106820151A (en) A kind of bivalve compound health composition, preparation method and application
WO2019235099A1 (en) Functional food
WO2011070767A1 (en) Prophylactic agent for atopic dermatitis
JP3749978B2 (en) Bone formation enhancing composition exhibiting anti-osteoporosis effect
JP2004217559A (en) Prophylactic and ameliorating agent for diabetic condition
CN111317775A (en) Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof
JP7091344B2 (en) Prebiotic dietary supplements to promote amylose-degrading activity and activity of short-chain fatty acid-producing microorganisms
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
CN109432242A (en) A kind of larch arabinogalactan preparation method and its application in terms of medical treatment
CN104161746A (en) Sugar-free lysine and gluconic acid zinc granule composition and preparation method thereof
CN109601880B (en) Health food for increasing bone mineral density
CN114128882A (en) Desert cistanche probiotic chewable tablet with function of relaxing bowel and preparation method and application thereof
TWI530256B (en) Method for producing anti-mental fatigue agent utilizing ferro-bound lactoferrin
JP7102347B2 (en) Use of insulin to promote gastric emptying
WO2011118067A1 (en) Immunostimulator comprising component derived from allium plant, process for production of immunostimulator, food composition, and immunostimulating method
CN115177658B (en) Composition for reducing blood sugar
CN111528386B (en) Hawthorn and natto solid beverage and preparation method thereof
KR20100056329A (en) Calcium compound and calcium compound fertilized rice for the prevention and treatment of osteoporosis
JPH06345660A (en) Sodium absorption inhibitor, sodium absorption inhibiting food and drink and feed and drink for animal

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination